US DOJ Flags Competition Law Concerns in Corteva V. Inari Plant Invention Dispute

Key Takeaways

• DOJ urges removal of post‑grant restrictions on deposited seed samples.
• Inari used Corteva’s deposited corn seeds to develop edited varieties.
• Court must balance patent exclusivity with competition and follow‑on innovation.
• MTAs may conflict with 37 C.F.R. § 1.808(a)(2) after patent issuance.
• Decision could set precedent for biotech seed IP and antitrust enforcement.

Pulse Analysis

The seed industry sits at the intersection of cutting‑edge biotechnology and traditional agriculture, making intellectual‑property protection a critical lever for revenue. Patents and plant‑variety protection certificates grant exclusive rights, but they also require inventors to deposit seed samples in public repositories. The DOJ’s intervention signals growing antitrust scrutiny of how those deposits are managed, especially when large firms use material‑transfer agreements to limit downstream use. By highlighting the statutory requirement that post‑grant restrictions be removed, the agency is urging a more open‑access model that could accelerate follow‑on research.

Material‑transfer agreements (MTAs) have become standard contracts governing seed deposits, often embedding clauses that forbid commercial exploitation or external shipment. However, 37 C.F.R. § 1.808(a)(2) mandates that any such constraints dissolve once a patent issues, preserving the public‑benefit bargain at the heart of the patent system. The DOJ’s stance challenges the legality of contractual add‑ons that extend a patent’s reach, arguing they undermine competition and the ability of researchers to “read” biological material. This legal tension raises questions about how depositories like ATCC will balance compliance with both contractual obligations and federal regulations.

The eventual court ruling will reverberate across the biotech seed market. A decision favoring broader public access could lower barriers for small‑scale breeders and solo inventors, fostering a more diverse pipeline of crop innovations. Conversely, a ruling that upholds restrictive MTAs may reinforce the dominance of major players such as Corteva, potentially stifling competition. Stakeholders—from venture‑backed startups to multinational agribusinesses—are watching closely, as the precedent will shape licensing strategies, R&D investment, and the overall competitive landscape of agricultural biotechnology.